Toxoplasma gondii | Appendix B: Panel Roster and Financial Disclosures | Adult and Adolescent Opportunistic Infection | ClinicalInfo

Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Updated

Jan. 01, 2020

Reviewed

Aug. 01, 2019

Appendix B: Panel Roster and Financial Disclosures

Toxoplasma gondii

*Toxoplasma gondii* Encephalitis
Member		Financial Disclosure
Member		Company	Relationship
Boyd, Sarita	Food and Drug Administration	None	N/A
Chow, Felicia	University of California, San Francisco	None	N/A
Kovacs, Joe*	National Institutes of Health	Matinas BioPharma	Research Support
Kovacs, Joe*	National Institutes of Health	Merck	Research Support
Kuruppu, Janaki	National Institutes of Health	None	N/A
Lai, Leon	Washington Hospital Center	None	N/A
Miro, Jose M.	Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain	None	N/A
Podzamczer, Daniel	Hospital Universitari de Bellvitge, Barcelona, Spain	None	N/A
* Group lead Note: Members were asked to disclose all relationships from 12 months prior to the update date. The period of reporting was from August 1, 2018, through August 1, 2019.

Download Guidelines

Section OnlyPDF (337.79 KB)
Full GuidelinePDF (3.78 MB)
Tables OnlyPDF (481.21 KB)